Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis.
Tuberculosis remains a global health problem, and programs dedicated to discovery of novel compounds against Mycobacterium tuberculosis require robust assays for high-throughput screening of chemical and natural product libraries. Enzymes involved in the biosynthesis of mycolic acids, vital components of the mycobacterial cell wall, have received much attention as potential drug targets. KasA and KasB, examples of the beta-ketoacyl-acyl carrier protein synthase I/II (KASI/II) class of condensing enzymes of the M. tuberculosis fatty acid synthase II system have been the focus of several studies designed to biochemically characterize these enzymes. Whilst robust methods have been developed for FabH-like proteins, fast and sensitive assays for high-throughput screening of KASI/II enzymes have not been available. Here we report the development of a direct scintillation proximity assay (SPA) for the KASI/II enzymes, KasA and KasB. The SPA was more sensitive than existing assays, as shown by its ability to measure activity using less enzyme than other assay formats, and the SPA was validated using the known KAS inhibitor thiolactomycin. In addition, the KasA and KasB SPA was adapted for use with Staphylococcus aureus FabF to show the versatility of this assay format to KAS enzymes from other pathogenic organisms.
Schaeffer
M L Merrill L
ML
GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. mschaeffer@bi-vetmedica.com
Carson
J D Jeffrey D
JD
Kallender
Howard
H
Lonsdale
J T John T
JT
D015099:3-Oxoacyl-(Acyl-Carrier-Protein) Synthase / Q000378:metabolism*; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002623:Chemistry Techniques, Analytical / Q000379:methods; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D050745:Enoyl-(Acyl-Carrier Protein) Reductase (NADPH, B-Specific); D004791:Enzyme Inhibitors / Q000494:pharmacology; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology*; D009171:Mycolic Acids / Q000378:metabolism*; D010088:Oxidoreductases / Q000378:metabolism*; D013211:Staphylococcus aureus; D013876:Thiophenes / Q000494:pharmacology; D013997:Time Factors
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D009171:Mycolic Acids; D013876:Thiophenes; C035068:thiolactomycin; D010088:Oxidoreductases; D050745:Enoyl-(Acyl-Carrier Protein) Reductase (NADPH, B-Specific); D015099:3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; D004121:Dimethyl Sulfoxide